Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31260115 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL31443460 | 0.89 | CHRM2 (0.45) | ALDH1A1CHRM2CHRM3L3MBTL1HTR2C | |
| SCHEMBL2625797 | 0.89 | CHRM2 (0.45) | ALDH1A1CHRM2CHRM3L3MBTL1HTR2C | |
| SCHEMBL2625790 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL2616323 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL24359312 | 0.78 | NOTUM (0.50) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL19703497 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL1282891 | 0.78 | DRD1 (0.53) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL520908 | 0.78 | BRD4 (0.51) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL17948564 | 0.78 | CYP1A2 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | ALDH1A1 188/4885MEN1 2160/4885KMT2A 4012/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | ALDH1A1 4344/4885MEN1 3335/4885KMT2A 869/4885 |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | ALDH1A1 188/4885MEN1 2160/4885KMT2A 4012/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | ALDH1A1 188/4885MEN1 2160/4885KMT2A 4012/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | ALDH1A1 188/4885MEN1 2160/4885KMT2A 4012/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885MEN1 4080/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.